Uncategorized

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock – December 14, 2023

Ocular Therapeutix™, Inc. announced the pricing of an underwritten public offering of 30,800,000 shares of its common stock at a public offering price of $3.25 per share for gross proceeds of $100.1 million, before deducting underwriting discounts and commissions and other offering expenses payable by the Company.

Ocular Therapeutix™ Announces Pricing of Public Offering of Common Stock – December 14, 2023 Read More »

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China’s National Reimbursement Drug List

Antengene Corporation Limited announced that XPOVIO® has been added to the National Reimbursement Drug List for the treatment of adult patients with relapsed or refractory multiple myeloma whose disease is refractory to at least one proteasome inhibitors, one immunomodulatory agent, and an anti-CD38 monoclonal antibody.

Antengene Announces Inclusion of XPOVIO® (selinexor) in 2023 China’s National Reimbursement Drug List Read More »

Genomma Lab Internacional Announces Sixth Dividend Payment – December 14, 2023

Genomma Lab Internacional, S.A.B. de C.V. informs that the Company filed a Notice of Rights with the Mexican Stock Exchange declaring a cash dividend of $0.196080 Mexican pesos per share on its common stock representing a total amount of $200,001,600.00 M.N., payable to shareholders of record of the applicable circulating shares at the close of

Genomma Lab Internacional Announces Sixth Dividend Payment – December 14, 2023 Read More »

Scroll to Top